N
Nashat Y. Gabrail
Researcher at University of Washington
Publications - 124
Citations - 4352
Nashat Y. Gabrail is an academic researcher from University of Washington. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 102 publications receiving 3831 citations.
Papers
More filters
Journal ArticleDOI
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen,Cornelis J A Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. Craig Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,Neal J. Meropol +13 more
TL;DR: The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Journal ArticleDOI
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
Steven J. Cohen,Cornelis J. A. Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. C. Miller,Gerald V. Doyle,H. Tissing,Leonardus Wendelinus Mathias Marie Terstappen,Neal J. Meropol +13 more
TL;DR: Baseline CTC count is an important prognostic factor within specific subgroups defined by treatment or patient characteristics, and unfavorable baseline CTC was associated with inferior PFS and overall survival.
Journal ArticleDOI
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann,Robert L. Coleman,Robert A. Burger,Edward A. Sausville,Elzbieta Kutarska,Sharad A. Ghamande,Nashat Y. Gabrail,Stephen E. DePasquale,Elżbieta Nowara,Lucy Gilbert,Robert H. Gersh,Michael Teneriello,Wael A. Harb,Panagiotis A. Konstantinopoulos,Richard T. Penson,James T. Symanowski,Chandra D. Lovejoy,Christopher P. Leamon,David Morgenstern,Richard A. Messmann +19 more
TL;DR: Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Albiruni Ryan Abdul Razak,Morten Mau-Soerensen,Nashat Y. Gabrail,John F. Gerecitano,Anthony F. Shields,Thaddeus J. Unger,Jean Richard Saint-Martin,Robert W. Carlson,Yosef Landesman,Dilara McCauley,Tami Rashal,Ulrik Lassen,Richard D. Kim,Lee Anne Stayner,Mansoor Raza Mirza,Michael Kauffman,Sharon Shacham,Amit Mahipal +17 more
TL;DR: Selinexor is a novel and safe therapeutic with broad antitumor activity and the recommended phase II dose of 35 mg/m2 given twice a week was chosen based on better patient tolerability and no demonstrable improvement in radiologic response or disease stabilization compared with higher doses.
Journal ArticleDOI
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky,Ian W. Flinn,Robert M. Rifkin,Nashat Y. Gabrail,Veena Charu,Billy Clowney,James Essell,Yousuf Gaffar,Thomas A. Warr,Rachel Neuwirth,Yanyan Zhu,Jennifer Elliott,Dixie-Lee Esseltine,Liviu Niculescu,James A. Reeves +14 more
TL;DR: Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.